Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients.
Haggenburg S, Lissenberg-Witte BI, van Binnendijk RS, den Hartog G, Bhoekhan MS, Haverkate NJE, de Rooij DM, van Meerloo J, Cloos J, Kootstra NA, Wouters D, Weijers SS, van Leeuwen EMM, Bontkes HJ, Tonouh-Aajoud S, Heemskerk MHM, Sanders RW, Roelandse-Koop E, Hofsink Q, Groen K, Çetinel L, Schellekens L, den Hartog YM, Toussaint B, Kant IMJ, Graas T, de Pater E, Dik WA, Engel MD, Pierie CRN, Janssen SR, van Dijkman E, Poniman M, Burger JA, Bouhuijs JH, Smits G, Rots NY, Zweegman S, Kater AP, van Meerten T, Mutsaers PGNJ, van Doesum JA, Broers AEC, van Gils MJ, Goorhuis A, Rutten CE, Hazenberg MD, Nijhof IS. Haggenburg S, et al. Among authors: mutsaers pgnj. Blood Adv. 2022 Mar 8;6(5):1537-1546. doi: 10.1182/bloodadvances.2021006917. Blood Adv. 2022. PMID: 35114690 Free PMC article. Clinical Trial.
Antibody Response in Immunocompromised Patients With Hematologic Cancers Who Received a 3-Dose mRNA-1273 Vaccination Schedule for COVID-19.
Haggenburg S, Hofsink Q, Lissenberg-Witte BI, Broers AEC, van Doesum JA, van Binnendijk RS, den Hartog G, Bhoekhan MS, Haverkate NJE, Burger JA, Bouhuijs JH, Smits GP, Wouters D, van Leeuwen EMM, Bontkes HJ, Kootstra NA, Zweegman S, Kater AP, Heemskerk MHM, Groen K, van Meerten T, Mutsaers PGNJ, Beaumont T, van Gils MJ, Goorhuis A, Rutten CE, Hazenberg MD, Nijhof IS; COBRA KAI Study Team. Haggenburg S, et al. Among authors: mutsaers pgnj. JAMA Oncol. 2022 Oct 1;8(10):1477-1483. doi: 10.1001/jamaoncol.2022.3227. JAMA Oncol. 2022. PMID: 35951338 Free PMC article.
Timely administration of tocilizumab improves outcome of hospitalized COVID-19 patients.
Rutgers A, Westerweel PE, van der Holt B, Postma S, van Vonderen MGA, Piersma DP, Postma D, van den Berge M, Jong E, de Vries M, van der Burg L, Huugen D, van der Poel M, Kampschreur LM, Nijland M, Strijbos JH, Tamminga M, Mutsaers PGNJ, Schol-Gelok S, Dijkstra-Tiekstra M, Sidorenkov G, Vincenten J, van Geffen WH, Knoester M, Kosterink J, Gans R, Stegeman C, Huls G, van Meerten T. Rutgers A, et al. Among authors: mutsaers pgnj. PLoS One. 2022 Aug 12;17(8):e0271807. doi: 10.1371/journal.pone.0271807. eCollection 2022. PLoS One. 2022. PMID: 35960720 Free PMC article. Clinical Trial.
R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma.
Al-Sarayfi D, Meeuwes FO, Durmaz M, Issa DE, Brouwer RE, Beeker A, van Rhenen A, Mutsaers PGNJ, Böhmer LH, van der Poel MWM, Te Boome L, van Meerten T, Chamuleau MED, Zijlstra JM, Brink M, Nijland M. Al-Sarayfi D, et al. Among authors: mutsaers pgnj. Blood Cancer J. 2022 Sep 2;12(9):125. doi: 10.1038/s41408-022-00723-4. Blood Cancer J. 2022. PMID: 36055987 Free PMC article. No abstract available.
Development of a Core Set of Patient- and Caregiver-Reported Signs and Symptoms to Facilitate Early Recognition of Acute Chimeric Antigen Receptor T-Cell Therapy Toxicities.
Spanjaart AM, Pennings ERA, Kos M, Mutsaers PGNJ, Lugtenburg PJ, van Meerten T, van Doesum JA, Minnema MC, Jak M, van Dorp S, Vermaat JSP, van der Poel MWM, van Oijen MGH, Kuipers MT, Nijhof IS, Kersten MJ. Spanjaart AM, et al. Among authors: mutsaers pgnj. JCO Oncol Pract. 2023 Mar;19(3):e407-e416. doi: 10.1200/OP.22.00501. Epub 2022 Dec 12. JCO Oncol Pract. 2023. PMID: 36508702 Free PMC article.
Fourth mRNA COVID-19 vaccination in immunocompromised patients with haematological malignancies (COBRA KAI): a cohort study.
Hofsink Q, Haggenburg S, Lissenberg-Witte BI, Broers AEC, van Doesum JA, van Binnendijk RS, den Hartog G, Bhoekhan MS, Haverkate NJE, van Meerloo J, Burger JA, Bouhuijs JH, Smits GP, Wouters D, van Leeuwen EMM, Bontkes HJ, Kootstra NA, Vogels-Nooijen S, Rots N, van Beek J, Heemskerk MHM, Groen K, van Meerten T, Mutsaers PGNJ, van Gils MJ, Goorhuis A, Rutten CE, Hazenberg MD, Nijhof IS; COBRA KAI study team. Hofsink Q, et al. Among authors: mutsaers pgnj. EClinicalMedicine. 2023 Jul;61:102040. doi: 10.1016/j.eclinm.2023.102040. Epub 2023 Jun 15. EClinicalMedicine. 2023. PMID: 37337616 Free PMC article.
Inflammatory reactions mimic residual or recurrent lymphoma on [18F]FDG-PET/CT after CD19-directed CAR T-cell therapy.
de Boer JW, Pennings ERA, Kleinjan A, van Doesum JA, Spanjaart AM, Mutsaers PGNJ, Jak M, van der Poel MWM, Kuipers MT, Adam JA, Diepstra A, Koens L, van Dorp S, Vermaat JSP, Niezink AGH, Kersten MJ, van Meerten T. de Boer JW, et al. Among authors: mutsaers pgnj. Blood Adv. 2023 Nov 14;7(21):6710-6716. doi: 10.1182/bloodadvances.2023010665. Blood Adv. 2023. PMID: 37639324 Free PMC article. No abstract available.
The Dutch CAR-T Tumorboard Experience: Population-Based Real-World Data on Patients with Relapsed or Refractory Large B-Cell Lymphoma Referred for CD19-Directed CAR T-Cell Therapy in The Netherlands.
Spanjaart AM, Pennings ERA, Mutsaers PGNJ, van Dorp S, Jak M, van Doesum JA, de Boer JW, Niezink AGH, Kos M, Vermaat JSP, Sijs-Szabo A, van der Poel MWM, Nijhof IS, Kuipers MT, Chamuleau MED, Lugtenburg PJ, Doorduijn JK, Serroukh YIM, Minnema MC, van Meerten T, Kersten MJ; Dutch CAR-T Tumorboard Consortium. Spanjaart AM, et al. Among authors: mutsaers pgnj. Cancers (Basel). 2023 Aug 30;15(17):4334. doi: 10.3390/cancers15174334. Cancers (Basel). 2023. PMID: 37686611 Free PMC article.
Population-Based External Validation of the EASIX Scores to Predict CAR T-Cell-Related Toxicities.
de Boer JW, Keijzer K, Pennings ERA, van Doesum JA, Spanjaart AM, Jak M, Mutsaers PGNJ, van Dorp S, Vermaat JSP, van der Poel MWM, van Dijk LV, Kersten MJ, Niezink AGH, van Meerten T; Dutch CAR-T Tumorboard Consortium. de Boer JW, et al. Among authors: mutsaers pgnj. Cancers (Basel). 2023 Nov 16;15(22):5443. doi: 10.3390/cancers15225443. Cancers (Basel). 2023. PMID: 38001703 Free PMC article.
35 results